Nearly 1 in 10 Cancer Patients May Not Receive Guideline-Concordant Care
The highest rate of non-concordant care was seen in patients with cervical cancer.
The highest rate of non-concordant care was seen in patients with cervical cancer.
Roughly half of patients with hematologic cancers or solid tumors lost neutralizing antibody responses to SARS-CoV-2 variants of concern at 6 months after vaccination.
Of the patients studied, 59% demonstrated poor prognostic understanding of curability.
The association between proton pump inhibitors and reduced efficacy of atezolizumab suggest “an urgent need” for evidence on how PPIs might impact other immune checkpoint inhibitors, according to researchers.
ECOG performance status was most strongly associated with death.
Survival outcomes were similar for patients with an extended dosing interval and patients who received standard dosing.
All patients achieved engraftment, and none developed complications associated with COVID-19.
In the platinum-pretreated cohort, the objective response rate was 28%.
RSK4-targeting floxacins could boost the efficacy of chemotherapy.
A single-center, retrospective cohort study was conducted to assess response to treatment and progression of disease in patients with severe lymphopenia undergoing treatment with immune checkpoint inhibitors for NSCLC.